名臣健康(002919) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥92,005,273.17, representing a decrease of 17.23% compared to ¥111,161,911.79 in the same period last year[7] - Net profit attributable to shareholders was ¥6,040,118.93, down 29.50% from ¥8,568,054.69 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥3,536,279.25, a decline of 49.80% compared to ¥7,044,243.52 in the previous year[7] - Basic and diluted earnings per share were both ¥0.05, down 28.57% from ¥0.07 in the previous year[7] - Total operating revenue for Q1 2020 was CNY 92,005,273.17, a decrease from CNY 111,161,911.79 in the previous period[36] - Net profit for Q1 2020 was CNY 6,040,118.93, compared to CNY 8,568,054.69 in the same period last year, representing a decline of approximately 29.5%[38] - The company's operating revenue for the current period is CNY 69,438,334.20, a decrease from CNY 91,944,181.68 in the previous period[41] - The net profit for the current period is a loss of CNY 892,044.98, compared to a profit of CNY 10,132,717.10 in the previous period[42] - The total comprehensive income for the current period is CNY -892,044.98, compared to CNY 10,132,717.10 in the previous period[43] Cash Flow and Liquidity - The net cash flow from operating activities improved by 30.01%, amounting to -¥48,653,019.41, compared to -¥69,511,979.59 in the same period last year[7] - Operating cash flow improved by 30.01%, with a net cash outflow of ¥48,653,019.41 compared to ¥69,511,979.59 in the previous year[15] - The cash flow from operating activities shows a net outflow of CNY 48,653,019.41, compared to a net outflow of CNY 69,511,979.59 in the previous period[46] - The net cash flow from operating activities was -46,417,337.84 yuan, compared to -69,179,070.58 yuan in the previous period, indicating an improvement of approximately 33%[49] - The net increase in cash and cash equivalents for the period was -206,069,370.11 yuan, compared to -19,818,192.65 yuan in the previous period, reflecting a significant decline[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥674,888,759.54, a decrease of 3.53% from ¥699,552,468.03 at the end of the previous year[7] - Total assets as of March 31, 2020, were CNY 640,712,377.00, down from CNY 671,106,756.32 at the end of 2019[34] - Current assets decreased to CNY 544,519,285.09 from CNY 572,090,185.87 at the end of 2019, reflecting a decline of about 4.8%[33] - Total liabilities decreased to CNY 55,625,265.04 from CNY 85,127,599.38, a reduction of approximately 34.6%[34] - Total assets decreased to ¥674,888,759.54 from ¥699,552,468.03, reflecting a decline in both current and non-current assets[15] Shareholder Information - The company reported a total of 10,009 common shareholders at the end of the reporting period[11] - The largest shareholder, Chen Qinfang, holds 49.34% of the shares, amounting to 60,258,000 shares, with 23,250,000 shares pledged[11] - The net assets attributable to shareholders increased by 1.06% to ¥571,426,267.02 from ¥565,434,654.72 at the end of the previous year[7] Government Support and Subsidies - The company received government subsidies amounting to ¥200,000 during the reporting period[8] - Other income increased by 100% to ¥200,000.00, attributed to government subsidies received during the period[15] Changes in Financial Position - Cash and cash equivalents decreased by 64.79% to ¥113,187,160.14 from ¥321,492,211.82 due to the purchase of financial products during the reporting period[15] - Trading financial assets increased by 156.80% to ¥263,940,709.59 from ¥102,779,726.03, primarily due to the addition of new financial products[15] - Accounts receivable rose by 51.18% to ¥28,842,972.62 from ¥19,078,453.24, influenced by extended credit terms for some customers due to the pandemic[15] - Investment cash flow turned negative at ¥-159,652,032.27, a decrease of 423.44% from a positive cash flow of ¥49,360,877.93, mainly due to the purchase of financial products[15] Operational Costs and Expenses - Total operating costs for Q1 2020 were CNY 86,477,657.11, down from CNY 102,232,144.81 in the previous period[37] - The company incurred research and development expenses of CNY 3,430,705.20, slightly down from CNY 3,612,961.52 in the previous period[41] - The cash paid for purchasing goods and services was 87,758,526.63 yuan, down from 115,108,079.78 yuan in the previous period, indicating a reduction in operational costs[49] Audit and Reporting Standards - The company has not yet audited the first quarter report, which may affect the reliability of the financial data presented[58] - The company has adopted new revenue and lease standards starting in 2020, which may impact future financial reporting and comparisons[57]